Table 1.

Patients with nonresistant GIST

Primary tumor locationHistologyDisease at imatinib startTime on imatinib* (months)Best clinical responseHistologic responsePrimary mutationSecondary mutationPhospho-KIT Y721
1SBSP, L22PR2, 3Ex 11 VYIDPTQL569-576delabsent (0 of 2)2, 3
2ASBSP, PE, L15PR2, 3Ex 11 P551H MY552-554delabsent (0 of 6) LOH (3 of 6)1
2BL20PR1, 2Ex 11 P551H MY552-554delabsent (0 of 3) LOH (3 of 3)3
3ASBSPE12SD1Ex 9 INS502AYabsent (0 of 1)NA
3BPE18SD1Ex 9 INS502AYabsent (0 of 3)1, 3
4SBSP, L3SD1Ex 9 INS502AYabsent (0 of 3)1
5rectumSP9PR4WTabsent (0 of 1)NA
6SBSP4SD2Ex 9 INS502AYabsent (0 of 1)1
7rectumSP6PR4Ex 11 VQWKV555-559delabsent (0 of 1)3
8SBSP2PR1Ex 11 K558N, INS559Qabsent (0 of 1)NA
9SBSPE, L1PR3, 4WTabsent (0 of 1)NA
10stomachSP8PR4Ex 11 WK557-558delabsent (0 of 1)NA
11stomachEPE5SD2, 3PDGFRA D842Vabsent (0 of 2)1
12SBSP, PE, L9PR4Ex 11 INGNNYVYIDPTQL563-576delabsent (0 of 2)3
13rectumSP8PR3Ex 13 K642Eabsent (0 of 1)2
14ASBSPE3PR4Ex 11 VYIDPTQL569-576delabsent (0 of 1)2
  • Abbreviations: SB, small bowel; S, spindle; E, epithelioid; P, primary tumor; PE, peritoneal; L, liver; PR, partial response; SD, stable disease; del, deletion; LOH, loss of heterozygosity; INS, insertion; NA, not available.

  • * Time from the start of imatinib to surgical resection.

  • Tested for KIT amplification by FISH.